Published in Circ Res on February 21, 2013
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Evidence for cardiomyocyte renewal in humans. Science (2009) 14.17
Concern Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet (2011) 11.45
Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation (2004) 4.79
Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation (2004) 4.31
Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation (2012) 2.83
Retracted Cardiomyogenesis in the aging and failing human heart. Circulation (2012) 2.16
Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation (2008) 1.68
Gene therapy for heart failure. Circ Res (2012) 1.46
An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res (2013) 1.41
Potential of gene therapy as a treatment for heart failure. J Clin Invest (2013) 1.04
Genetically manipulated progenitor/stem cells restore function to the infarcted heart via the SDF-1α/CXCR4 signaling pathway. Prog Mol Biol Transl Sci (2012) 0.87
Heterogeneity in SDF-1 expression defines the vasculogenic potential of adult cardiac progenitor cells. PLoS One (2011) 0.84
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med (2007) 3.98
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med (2012) 3.53
Functional near-infrared fluorescence imaging for cardiac surgery and targeted gene therapy. Mol Imaging (2002) 3.37
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet (2010) 3.36
Titin isoform switch in ischemic human heart disease. Circulation (2002) 3.05
Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail (2009) 2.89
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis (2006) 2.72
Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res (2005) 2.52
Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol (2008) 2.29
Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res (2013) 2.12
In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation (2004) 2.11
Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res (2012) 2.06
Effects of Na(+)/Ca(2+)-exchanger overexpression on excitation-contraction coupling in adult rabbit ventricular myocytes. J Mol Cell Cardiol (2002) 2.00
Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci U S A (2002) 1.98
Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol (2002) 1.97
Critical role for stromal interaction molecule 1 in cardiac hypertrophy. Circulation (2011) 1.91
SUMO1-dependent modulation of SERCA2a in heart failure. Nature (2011) 1.89
PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility. Circ Res (2006) 1.80
Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med (2013) 1.78
Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci U S A (2004) 1.77
Angiotensin II-induced negative inotropy in rat ventricular myocytes: role of reactive oxygen species and p38 MAPK. Am J Physiol Heart Circ Physiol (2005) 1.73
Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. Mol Ther (2006) 1.71
Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery to restore electrical stability in the failing heart. Circulation (2012) 1.71
Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation (2009) 1.71
Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol (2008) 1.70
Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit+ cells. Circ Res (2012) 1.68
Cardiac sodium channel gene variants and sudden cardiac death in women. Circulation (2007) 1.67
PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling. Circ Res (2008) 1.66
CaMKII inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion injury. Cardiovasc Res (2006) 1.64
Increased leakage of sarcoplasmic reticulum Ca2+ contributes to abnormal myocyte Ca2+ handling and shortening in sepsis. Crit Care Med (2005) 1.63
SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. Sci Transl Med (2013) 1.59
Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes. J Mol Cell Cardiol (2011) 1.55
Targeting phospholamban by gene transfer in human heart failure. Circulation (2002) 1.55
Inhibition of PKCα/β with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury. Circ Res (2011) 1.55
Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol (2007) 1.54
Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res (2009) 1.52
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol (2004) 1.46
Gene therapy for heart failure. Circ Res (2012) 1.46
Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. Circ Arrhythm Electrophysiol (2009) 1.44
Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol (2009) 1.42
Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J Clin Invest (2011) 1.42
AKT signalling in the failing heart. Eur J Heart Fail (2011) 1.41
Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther (2010) 1.41
SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ Arrhythm Electrophysiol (2011) 1.40
Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol (2008) 1.35
A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol (2011) 1.35
Distinct roles of microRNA-1 and -499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. PLoS One (2011) 1.34
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther (2011) 1.34
Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res (2005) 1.33
CXCR4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol (2006) 1.31
Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation (2008) 1.30
Localization and quantification of platelet-rich thrombi in large blood vessels with near-infrared fluorescence imaging. Circulation (2006) 1.28
The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis. J Mol Cell Cardiol (2010) 1.27
Novel technique of aortic banding followed by gene transfer during hypertrophy and heart failure. Physiol Genomics (2002) 1.27
Plasticity of surface structures and β(2)-adrenergic receptor localization in failing ventricular cardiomyocytes during recovery from heart failure. Circ Heart Fail (2012) 1.23
The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med (2008) 1.21
Early repair of moderate ischemic mitral regurgitation reverses left ventricular remodeling: a functional and molecular study. Circulation (2007) 1.20
A novel mutant cardiac troponin C disrupts molecular motions critical for calcium binding affinity and cardiomyocyte contractility. Biophys J (2008) 1.18
SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther (2010) 1.18
Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit Care Med (2007) 1.16
Ca2+ cycling and new therapeutic approaches for heart failure. Circulation (2010) 1.16
Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J (2013) 1.15
Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy. Nat Rev Cardiol (2012) 1.15
Shrink-film configurable multiscale wrinkles for functional alignment of human embryonic stem cells and their cardiac derivatives. Adv Mater (2011) 1.14
Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. J Clin Invest (2014) 1.13
Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. Stem Cells Transl Med (2013) 1.13
Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol (2003) 1.12
Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1alpha. J Nucl Med (2008) 1.12
Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med (2008) 1.12
Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol (2011) 1.11
In vivo cardiac gene transfer of Kv4.3 abrogates the hypertrophic response in rats after aortic stenosis. Circulation (2004) 1.11
Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol (2010) 1.10
Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol (2006) 1.09
Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells. Cell Reprogram (2010) 1.08
Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc (2013) 1.08
β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol (2010) 1.08
Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology (2006) 1.08
Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol (2006) 1.06
SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur Heart J (2012) 1.05
Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. J Biol Chem (2011) 1.05
Cardiac gene therapy with SERCA2a: from bench to bedside. J Mol Cell Cardiol (2010) 1.05
Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. Circulation (2013) 1.05
Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol (2005) 1.04
Intracellular devastation in heart failure. Heart Fail Rev (2008) 1.04
Comparison of nonuniform rotational distortion between mechanical IVUS and OCT using a phantom model. Ultrasound Med Biol (2007) 1.04
New efficient catheter-based system for myocardial gene delivery. Circulation (2002) 1.03
PICOT is a critical regulator of cardiac hypertrophy and cardiomyocyte contractility. J Mol Cell Cardiol (2008) 1.03
Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods (2013) 1.02
Bone morphogenetic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth muscle cell calcification. J Am Heart Assoc (2012) 1.01
Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis. Basic Res Cardiol (2010) 1.00
Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ Heart Fail (2010) 1.00
Damped elastic recoil of the titin spring in myofibrils of human myocardium. Proc Natl Acad Sci U S A (2003) 0.99
Gene therapy in the treatment of heart failure. Physiology (Bethesda) (2007) 0.98
Ventricular arrhythmias after left ventricular assist device implantation. Pacing Clin Electrophysiol (2008) 0.97
Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol (2010) 0.97